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The first generation of genome-wide association studies (GWA studies) for psychiatric
disorders has led to new insights regarding the genetic architecture of these disorders. We
now start to realize that a larger number of genes, each with a small contribution, are likely to
explain the heritability of psychiatric diseases. The contribution of a large number of genes to
complex traits can be analyzed with genome-wide profiling. In a discovery sample, a genetic
risk profile for depression was defined based on a GWA study of 1738 adult cases and 1802
controls. The genetic risk scores were tested in two population-based samples of elderly
participants. The genetic risk profiles were evaluated for depression and anxiety in the
Rotterdam Study cohort and the Erasmus Rucphen Family (ERF) study. The genetic risk
scores were significantly associated with different measures of depression and explained
up to B0.7% of the variance in depression in Rotterdam Study and up to B1% in ERF study.
The genetic score for depression was also significantly associated with anxiety explaining up
to 2.1% in Rotterdam study. These findings suggest the presence of many genetic loci of small
effect that influence both depression and anxiety. Remarkably, the predictive value of these
profiles was as large in the sample of elderly participants as in the middle-aged samples.
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Introduction
Genetic factors have an important role in the
susceptibility to depression. A meta-analysis of
twin studies on major depressive disorder (MDD)
estimated the heritability at 37%.
1 However, the
success of studies aiming to find genes underlying
the vulnerability for depression has been limited. An
overview of promising results of linkage studies on
MDD and neuroticism, a related personality trait,
shows some overlap in regions of interest, but, so far,
no single locus has been identified.
2 Candidate
gene studies, mostly focusing on genes involved in
neurotransmitter circuits or in reactions to stress,
have also not been able to unambiguously identify a
genetic variants explaining differences in the vulner-
ability for depression.
3,4
An important issue in research on the etiological
factors of MDD has been the frequent comorbidity
with anxiety disorders. In the National Comorbidity
Survey Replication, 59% of the subjects with a
lifetime diagnosis of MDD also fulfilled the criteria
for a lifetime anxiety disorder diagnosis.
5 A review
of twin and family studies indicated that this
comorbidity might be explained by shared, mostly
genetic factors.
6 Still, an overview of promising
results of linkage studies of anxiety only showed
one overlapping region of interest with MDD and
neuroticism.
2
The recent success of genome-wide association
(GWA) studies has fueled expectations on finding
genes for MDD. One of the first GWA studies of
depression showed evidence for the role of the
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7,8 Recently,
this result was replicated with a P-value of 210
9 in
a meta-analysis of the results in three population-
based samples, but not when five clinical samples
were also included.
7,9 However, the first GWA studies
of MDD as well as those of other psychiatric
phenotypes have also shown that genome-wide
significant findings are rare and explain a small part
of heritability.
7,10,11 This might be due to a lack of
power. The Genetic Association Information Network
(GAIN)-MDD GWA study, for example, including
B1700 cases and 1800 controls, had 80% statistical
power to detect relative risks of 1.59, 1.40 and 1.35
with a P-value of 110
7, for minor allele frequencies
of 0.10, 0.25 and 0.40. This is well comparable to
other first generation GWA studies. However, the first
results of GWA studies suggest that the strongest odds
ratios may be <1.2.
12 Another explanation for the
scarce genome-wide significant findings could be that
there is not a distinct number of genes for MDD with
moderate-to-small risks but rather a large number of
variations spread over the genome, each with small
effects. Such a polygenic model predicts that the more
markers are used, the better the disease is predicted
and it implies that everybody carries risk variants but
patients carry more than non-diseased people. We
examined if a polygenetic component influences
MDD implying that a large number of genetic variants
are involved in explaining its heritability.
The evidence for a polygenic origin has recently
been examined for schizophrenia and the hypothesis
of a polygenic component was directly tested using
GWA data.
13 In this approach, the joint effect of
multiple single-nucleotide polymorphisms (SNPs) are
tested rather than the effects of individual SNPs.
These individual SNPs are not required to reach a
genome-wide significance level by themselves. This
approach aims to test whether the genetic disease
liability reflects, at least in part, the additive effect of
a large number of variants spread across the genome
whose joint action may be captured in a genome-wide
genetic risk score. To obtain this risk score, a
discovery set is used to select SNPs based on specific
P-value thresholds (for example, 0.0001, 0.001, 0.01,
and so on) from a genome-wide scan for the disease of
interest. In the target samples, genetic risk scores are
calculated for each individual for each set of SNPs.
The selected SNPs will contain false positives but if
they are enriched with true-associated variants with
low effect size then the genetic risk score might still
be significantly associated with the disease in an
independent sample. The problem is to distinguish
truly associated SNPs from the false positives, which
occur massively around liberal P-value thresholds. In
the schizophrenia study, the genetic risk scores based
on the multiple SNPs in the discovery sample were
associated with schizophrenia in three independent
samples. The variance explained by the risk scores
increased as more SNPs were included, that is, risk
scores based on SNPs that had a P-value below 0.5 in
the discovery sample explained more variance in the
replication sample than the risk scores based on SNPs
selected at P-value below 0.1.
13 Moreover, the genetic
risk scores for schizophrenia were also significantly
associated with bipolar disorder assessed in two
samples suggesting that the genes influencing schizo-
phrenia and bipolar disorder partly overlap.
This study applied the risk score approach to
investigate whether a polygenic component can be
detected for depression and whether this polygenic
component also influences anxiety. As the study
samples differ in age, differences in the effect of the
polygenic component may indicate that the genetic
factors influencing depression and/or anxiety differ
across the lifespan. Twin studies have already shown
that the relative influence of genetic factors for
depression decreases with age,
14–16 but that the genes
influencing depression remain the same across the
years.
17 This can be investigated directly in this study.
The discovery set consisted of the GAIN–MDD
sample, including 1738 cases and 1802 controls
7,18
with over 400000 SNPs genotyped. The target sets
consisted of two independent Dutch samples. The
first sample was based on the Rotterdam Study cohort
and consisted of 178 depressive disorder patients
diagnosed according to Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV)
and 915 controls at low liability of depression as well
as 222 cases for anxiety and 290 controls at low
liability for anxiety. The second target sample was the
Erasmus Rucphen Family (ERF) study in which
symptoms of anxiety and depression were measured
in 1886 participants. The subjects in the GAIN–MDD
sample and the ERF sample were around 45 years of
age. The Rotterdam sample was an elderly sample
with a mean age of around 70. Height and intraocular
pressure (IOP), phenotypes unrelated to psychiatric
disorders, were additionally analyzed to examine if
the association with the genetic risk scores was
specific to depression and anxiety.
Materials and methods
Discovery sample
The discovery sample consisted of subjects from two
large-scale longitudinal studies: the Netherlands
Study of Depression and Anxiety
19 and the Nether-
lands Twin Registry.
20 The chances of success of
genetic risk score analyses depend primarily on the
size of the discovery or training set. If the sample size
is too small, the risk profiles will be based on random
noise and are not expected to explain variance in the
target set. To increase the chances of success, the
power of the discovery set should therefore be
maximized.
21 The size of the GAIN–MDD study made
it more suitable to be used as the discovery set than
the Rotterdam and ERF studies, which thus supplied
the target samples.
The Netherlands Study of Depression and Anxiety
and the Netherlands Twin Registry studies were
approved by the medical ethics committee of all
participating institutes. Collection of the phenotype
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as the statistical methods are described in detail
elsewhere.
7,18 In brief, inclusion criteria for MDD
cases were a lifetime diagnosis of DSM-IV MDD
22
assessed with the Composite International Diagnostic
Interview,
23 age of 18–65 years and self-reported
western European ancestry. Persons who were not
fluent in Dutch and those with a primary diagnosis of
schizophrenia or schizoaffective disorders, obsessive-
compulsive disorder, bipolar disorder or severe
substance use dependence were excluded. Inclusion
criteria for control subjects were availability of
biological samples and survey data with assessments
of depression, anxiety and neuroticism, no report of
MDD at any measurement occasion and low genetic
liability for MDD based on the survey data. In
addition, controls and their parents were required to
have been born in the Netherlands or Western Europe.
Only one control per family was selected. The cases
and controls were carefully matched on age and sex.
The genotypic data used in the discovery sample
were part of one of the six initial GAIN studies
sponsored by the Foundation for the National Institutes
of Health (NIH).
20 Individual genotyping was conducted
by Perlegen Sciences (Mountain View, CA, USA) using
a set of four proprietary, high-density oligonucleotide
arrays. The SNPs on these arrays were selected to tag
common variation in the HapMap European and Asian
panels. Of the 3820 samples sent to Perlegen, genotypes
were delivered for 3761 samples (98.5%) of which 3540
subjects passed quality controls and were available in
the final analysis data set including 1738 MDD cases
and 1802 controls. The SNP quality control process and
the precautions against population stratification are
detailed in Sullivan et al.
7 A total of 427037 SNPs on
chromosome 1 to chromosome 22 met all selection
criteria and were included in the final association
analyses, which were performed in PLINK.
24
Target samples
Rotterdam study. The Rotterdam Study is a
prospective cohort study in the district Ommoord of
Rotterdam.
25 In 1990, all inhabitants aged 55 years
and over were invited and 7983 persons agreed to
participate. The medical ethics committee of the
Erasmus Medical Center, Rotterdam, approved the
study. Written informed consent was obtained from
all participants.
Ascertainment of depressive symptoms and inci-
dent depressive disorders was described previously.
26
Depression and anxiety symptoms were assessed with
the Center for Epidemiological Studies Depression
Scale (CES-D) and Hospital Anxiety and Depression
Scale (HADS). The CES-D scale consists of 20 items
with scores ranging from 0 to 60. A score of 16 or
higher on the CES-D is considered indicative of a
depressive disorder. The HADS-Depression (HADS-D)
and HADS-Anxiety (HADS-A) scales each consist of
seven items with scores ranging from 0 to 21 with
higher scores indicating more symptoms of depres-
sion. These questionnaires are valid and reliable
self report measures of symptoms of depression.
27,28
The HADS was assessed during the second visit
in a randomly selected subgroup of individuals
(N=2231). Depression was measured with the CES-
D three times during the follow-up.
Among 7983 subjects who agreed to participate,
5974 were successfully genotyped, 524 died before
depression screening and 747 did not participate in
depression screening. In the remaining sample, 587
persons scoring higher than 16 on the CES-D in the
third or fourth visit were invited for a semi-structured
interview with the Present State Examination
29 by a
clinician. In addition, general practitioner records and
specialist letters were surveyed actively for the
occurrence of depression. Furthermore, physicians
conducted repeated interviews to assess self-reported
depression in the interval period. This effort identified
178 persons with current DSM-IV defined depressive
disorder (145 MDD, 15 dysthymia and 18 depression-
not otherwise specified cases) and eligible genotype
data. The control group consisted of 915 persons, who
scored in the lowest quartile (CES-D=‘0’) on CES-D in
the third visit (N=3879) and who did not report any
depressive symptoms during the follow up.
Anxiety disorders were assessed during the fourth
visit in the total sample by trained lay interviewers
who conducted a slightly adapted version of the
Munich Composite International Diagnostic Interview
to obtain DSM-IV diagnoses of generalized anxiety
disorder, panic disorder, agoraphobia, social phobia
and specific phobia. Obsessive compulsive disorder
and post-traumatic stress disorder were not included.
The current sample is selected from the 2779 persons
who had valid Munich Composite International
Diagnostic Interview assessment and genotype data.
Out of 2779, 222 persons were anxiety disorder cases.
The control group consists of 290 persons who did
not have any anxiety disorder and scored in the
lowest quartile (HADS-A=0) on the HADS-A mea-
sured in 1322 persons of the interviewed and sample
with eligible genotype data during the second visit.
Genome-wide SNP data were available from the
Illumina HumanHap550K (Illumina, Inc., San Diego,
CA, USA) array for all cases and controls. Data were
excluded based on call rate <97.5%, sex mismatch,
excess autosomal heterozygosity and outliers identi-
fied by the clustering analysis. MACH 1.0 software
(v1.0.16)
30,31 was used to impute to B2.54 million
SNPs based on the HapMap CEU phased haplotypes
(release 22). SNPs included in imputation met thresh-
olds of minor allele frequency (MAF) X1%, Hardy-
Weinberg equilibrium (HWE) P-value X10
6 and SNP
call rate X98.0%. GWA analysis of MDD was
performed with Mach2Dat (logistic regression on
allele dosage) using the GRIMP interface.
30,32 Age
and sex were included as covariates in the analysis.
ERF study
The ERF study is part of the Genetic Research in
Isolated Population program. The study population
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dents from 20 related couples who lived in the isolate
between 1850 and 1900 and had at least six children
baptized in the community church. The detailed
information regarding ERF isolate can be found
elsewhere.
33–35 The medical ethical committee of the
Erasmus Medical Center, Rotterdam approved the
study and informed consent was obtained from all
participants.
Symptoms of depression and anxiety were assessed
using the HADS and the CES-D
27,28 in 2385 partici-
pants who also underwent an extensive medical
examination.
Data on height and IOP were collected during the
medical examination. The height of participants
was determined using a stadiometer and bilateral
IOP measurements were performed using Goldmann
applanation tonometry.
36
Among 2385 persons with phenotypes, high-den-
sity genotype data were available for 1886 subjects.
The genotype data were available for this population
on four different genotyping platforms which were
Illumina 6K, Illumina 318K, Illumina 370K and
Affymetrix 250K (Affymetrix, Inc., Santa Clara, CA,
USA), which were merged and B2.5410
6 SNPs
were imputed using MACH 1.0 software (v1.0.16),
30,31
using build 36 HapMap (release 22) CEU population
as reference. Within each genotyping batch, only
SNPs showing a call rate >98%, MAF>1% and HWE
P-value >10
6 were used for imputations.
As the ERF study included related individuals,
GWA analyses were performed using a mixed model
by ‘mmscore’ option in GenABEL software,
37 which
combines the Family Based Score Test for Association
(FASTA) method of Abecasis et al.,
38 and kinship
matrix estimated from genotyped SNPs.
39
Risk score profiling
The score profiling method tests the association of a
genetic score variable that reflects a combined effect
of a number of selected SNPs with a trait. For a more
detailed description of the method, we refer to Purcell
et al.
13 In brief, SNPs were selected using the results
from the GAIN-MDD GWA studies
7 (the ‘discovery
sample’). These sets of SNPs were used to calculate
the genetic scores in the target samples. SNPs were
selected on the basis of their nominal P-value
(Pdiscovery) for association with MDD in the discovery
sample. Genetic risk scores were calculated for
Pdiscovery thresholds ranging from 0.00001 to 1.0.
Only those SNPs were included that were directly
genotyped in the discovery set (N=427049 SNPs). To
avoid ambiguity A/T G/C SNPs were excluded. As an
A to T or G to C change will result in the same
nucleotides on the opposite strands, this change might
be missed during the genotype analysis. SNPs for which
the quality of imputation had an R
2<0.95 in target
samples were also excluded. After all quality checks
and exclusions, a total of 181582 SNPs that were
available in both ERF and Rotterdam study samples
were selected for calculations of genetic risk scores.
For each individual in the two independent target
samples, the genetic score was calculated by multi-
plying the number of risk alleles per SNP (0, 1 or 2)
with the log odds ratio, summed over all SNPs in the
considered set of SNPs.
40 We calculated individual
scores for each set of SNPs using the PLINK (v1.06)
software.
24
Logistic regression models were used to test the
association of the individual genetic risk scores for
depressive and anxiety disorders. Linear regression
models were used to test the association between
genetic risk scores and the total CES-D, HADS-D and
HADS-A scores as well as for height and IOP. Sex and
age were used as covariates. As an alternative control
for false positivity, 10% of the non-associated cluster
of SNPs with Pdiscovery>0.9 (N=1569 SNPs) in the
discovery set was selected and used for computing
the risk profile in both target samples.
For the Rotterdam Study regression analysis were
performed in SPSS 15.0 for Windows (SPSS, Chicago,
IL, USA). As the ERF sample includes relatives, data
are not independent, which can lead to biased
estimates of standard errors and test statistics if this
dependency between measures is not taken into
account.
41 Association analysis of genetic risk score
and the traits in ERF population were performed in
Sequential Oligogenic Linkage Analysis Routines
4.1.5 software package (Southwest Foundation for
Biomedical Research, San Antonio, TX, USA)
42 using
the ‘polygenic’ option to adjust for pedigree kinship.
Among 1886 people both genotyped and phenotyped,
1697 were clustered into pedigrees (using the pedi-
gree splitting algorithm PedCut
43) and included in the
family-based analysis. The remaining persons were
not included in the analysis because they were also
(distantly) related. The difference of the explained
variance in the null and alternative model was
considered as the variance explained by the genetic
score. A genetic risk score with a P-value <0.05 in the
model was considered as significantly associated
with the trait.
Results
Table 1 shows the descriptive data for the case–
control studies of GAIN–MDD and the Rotterdam
Study, and Table 2 for the ERF study. As in the
Rotterdam study subjects were ascertained on the
basis of age 55 or more, the mean age was 74 years.
This was higher than in the GAIN–MDD and ERF
study in which the mean ages were around 45 years.
Level of education was higher in the GAIN–MDD
sample than in the other two samples. In the target
samples, subjects diagnosed with a depressive dis-
order or an anxiety disorder were more often women
and were older. In the discovery sample, cases and
controls were matched based on age and sex.
In the ERF study, CES-D, HADS-D and HADS-A
scores were highly correlated (rB0.7 pair wise for all
three). Figure 1a shows the variance explained by the
genetic risk scores in the logistic regression analyses
Common genetic variants in depression and anxiety
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disorder as dependent variable. The genetic score
based on the first cluster of six SNPs (Pdiscovery <0.00001)
significantly explained 0.66% of the variance in
depressive disorder in the Rotterdam Study
(P=0.03). This association is explained in large part
by a cluster of three SNPs (rs2715148, rs2522833 and
rs2522840) in the PCLO gene as after removing the
PCLO SNPs in linkage disequilibrium (LD), the risk
score was not significantly associated with depres-
sion in the target sample anymore. More importantly,
the scores based on SNPs with Pdiscovery <0.1 to
Pdiscovery<0.4 were associated with depressive disor-
der in the Rotterdam Study explaining up to 0.65% of
the variance, with a P<0.05. As shown in Figure 1b,
the Rotterdam Study anxiety disorder case–control
sample analysis yielded the highest percentage of
variance explained with the genetic risk scores from
GAIN–MDD study. The risk scores based on SNPs
with Pdiscovery<0.1 to Pdiscovery<1.0 significantly ex-
plained up to 2.1% of the variance (P=0.0025). For
Pdiscovery values of 0.1, 0.2 and 0.3, the percentage of
variance increased from 1 to 2% when a higher
number of SNPs were included in risk scoring.
Figures 2a–c show the linear regression results for
the analysis using the continuous scores on the CES-
D, HADS-D and HADS-A in the ERF study. For CES-
D, the scores based on SNPs with Pdiscovery values
<0.01 and 0.1 explained B0.5% of the variance
(P=0.007 and P=0.008). For the HADS-D, the score
based on SNPs with Pdiscovery<0.01 significantly
explained 0.3% of the variance (P=0.03). The MDD-
based genetic score was also significantly associated
with anxiety measured with the HADS-A explaining
up to 0.5% of the variance (P=0.01).
To examine whether these results were due to
chance, we tested whether the MDD-based genetic
risk score predict also variation in height and IOP
measured in ERF. Heritability of IOP was 35% and
86% for height
36,44 and none of the traits was
correlated to depression or anxiety in the ERF study.
The genetic risk score for MDD failed to predict IOP
and height (Figures 3a and b) suggesting that this
relation is specific to depression and anxiety. More-
over, a genetic score of SNPs with Pdiscovery<0.9 in the
discovery set did not show significant association
with any of the phenotypes in the target samples (data
not shown).
Discussion
The aim of this study was to investigate the genetic
architecture of depression and the potential overlap
Table 2 Descriptive data of ERF study
Mean (s.d.)
CES-D 10.6 (9.6)
HADS-D 5.9 (4.3)
HADS-A 6.7 (4.5)
Age, mean (s.d.) 48.2 (14.7)
Women (%) 57.4
Education (%)
Elementary 30.8
Intermediate 63.8
Higher 5.4
Antidepressant medication (%) 5.0
Abbreviations: CES-D, Center for Epidemiological Studies
Depression Scale; ERF, Erasmus Rucphen Family; HADS-A,
Hospital Anxiety and Depression Scale-Anxiety subscale;
HADS-D, Hospital Anxiety and Depression Scale-Depres-
sion subscale.
Table 1 Descriptive data of case–control samples
Gain-MDD Rotterdam study DD Rotterdam study AD
Cases
(N=1738)
Controls
(N=1802)
Cases
(N=178)
Controls
(N=915)
Cases
(N=222)
Controls
(N=290)
Age, mean (s.d.) 42.6 (12.6) 45.1 (14.1) 67.7 (6.8)
a 64.8 (6.5)
a 75.4 (5.82) 74.6 (5.32)
Women (%) 69.6 62 75.7 43.5 78 43
Education (%)
Elementary 7.8 5.7 41.8 22.7 37.2 19.4
Intermediate 62 56.3 53.7 64.5 56.4 64.6
Higher 32.2 38.1 4.5 12.8 6.4 16.0
Antidepressant medication (%) 34.5 0 12.4
a 0
a 12.1 2
Comorbid AD/MDD (%) 69.9 0 35.8
b 3.6
c 10.8 0.7
Abbreviations: AD, anxiety disorder; DD, depressive disorder; GAIN, Genetic Association Information Network; MDD, major
depressive disorder.
aRecorded at baseline.
bData available in 108 out of 178 cases.
cData available in 701 out of 915 controls.
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availability of an elderly cohort, it was also possible
to examine whether the genetic factors influencing
anxiety and depression change across the life span.
Using genetic risk scores derived from the association
results of the GAIN–MDD study in two independent
target samples, we evaluated the evidence for a
genome-wide signature for several measures of de-
pression and anxiety used as outcome variables in
the target samples. For depression, either diagnosed
according to the DSM-IV or measured with the
CES-D or HADS-D, we could explain up to B1% of
the variance with the genetic risk scoring approach.
Moreover, the genetic risk scores for depression were
also associated with anxiety explaining up to 2.1% of
the variance when approximately half of the genome-
wide SNP data were included in the score. The
explained variance was highest in the elderly sample
indicating that the genetic factors influencing anxiety
and depression hardly change with age. No signifi-
cant results were found for the control variables
height and IOP, implying that the association of the
genetic risk score with depression and anxiety does
not reflect chance alone. Overall, these findings
suggest the presence of many loci, each with a small
effect influencing depression as well as anxiety.
We checked whether our results were only because
of SNPs in high LD segregating together. We per-
formed a strict LD pruning (200 SNPs sliding window
with r
2
snpsnp threshold of 0.25). Considering the
CES-D scale in ERF study, percentage of variance
explained by the risk scores based on SNPs with
Pdiscovery<0.01 dropped slightly after LD pruning from
0.52 to 0.49 but remained significant (P=0.01)
whereas a less strict pruning with an r
2
snpsnp thresh-
old of 0.50 improved the percentage of explained
variance to 0.62 (P=0.0003). Results with HADS-A
and HADS-D scales were similar which shows that LD
pruning itself does not add a major difference to the
method (data not shown). Excluding the SNPs with
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Figure 1 Percentage of variance explained by genetic risk scores in Rotterdam Study. Percentage of variance represented as
difference in Nagelkerke R
2 after adjustment for age and sex. (a) Analyses based on comparison of DD persons (n=178) to
persons scoring in the lowest quartile of CES-D (CES-D=‘0’) scale and who did not report any depressive complaints during
the follow-up (n=915). (b) Analyses based on comparison of persons with anxiety disorder (n=222) to persons scoring in the
lowest quartile of HADS-A (HADS-A=‘0’) scale and who did not report any depression or anxiety symptoms during the
follow-up (n=290). *P value <0.05, **P value <0.001.
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Molecular Psychiatryminor allele frequency <0.05 did not change the
explained variance. This finding suggest the common
disease common variant hypothesis is explaining
MDD heritability, on the other hand, the power to
detect the effect of rare variants in the discovery and
target sets, was low and such rare variants may be
detected by other approaches such as linkage or deep
sequencing.
Our results are in agreement with the results from
the International Schizophrenia Consortium
13 that
pointed out a polygenic component influencing
schizophrenia as well as bipolar disorder. There was
a somewhat higher amount of explained variance for
schizophrenia (3.2% compared with 1%). This may
be due to power issues such as differences in sample
size (B3300 cases for International Schizophrenia
ERF Study CES-D scale
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Figure 2 Percentage of variance explained in depression and anxiety symptoms in ERF study by the genetic risk scores.
Percentage of variance represented as difference in R
2 after adjusting for age sex and family relations. (a–c), analyses of
continuous scales. *P value <0.05, **P value <0.01.
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Molecular PsychiatryConsortium vs B1800 cases for GAIN–MDD), MDD
being a common disease with clear non-genetic
influence because of life events, and lower heritabil-
ity compared with schizophrenia (B40 vs B80%).
The percentage of explained variance in anxiety
(2.1%) supports the idea of shared genetic back-
ground between these disorders. This has already
been suggested by twin studies
45 and is confirmed by
our results. The trend of an increase in R
2 for anxiety
with different Pdiscovery thresholds is different from the
trend that we observe in depression, pointing out that
the effect sizes are different, but the direction of effect
is the same. We would like to stress that difference in
explained variance between the target samples can
evenly well be explained by chance. Moreover, it is
important to note that 70% of the GAIN–MDD cases
had a comorbid lifetime anxiety diagnosis. However,
this high comorbidity is exactly what is expected if
two disorders are influenced by similar genes and
diagnoses are not mutually exclusive. Future re-
search, preferably with a more balanced proportion
of pure depressed and comorbid cases, can shed more
light on the overlap in genetic factors influencing
anxiety and depression.
A limitation of this study was that there were some
differences between the discovery set and the target
samples. Different instruments were used to measure
depression and anxiety. In the GAIN–MDD study, the
Composite International Diagnostic Interview was
used to diagnose MDD and anxiety disorders, while
in the Rotterdam study, the Present State Examination
(PSE) was used. However, both instruments aim to
make diagnoses according to the DSM-IV criteria and
have adequate agreement for overall syndromes.
46 In
the ERF population, symptoms of depression and
anxiety were measured using the CES-D and HADS.
Several validation studies on various types of patients
using different diagnostic tools have shown that
HADS performs well in assessing the symptom
severity and case status of anxiety disorders and
depression in both somatic, psychiatric and primary
care patients and in the general population.
47 The
HADS-D subscale has shown high sensitivity (B0.9)
and specificity (B0.7) for MDD as diagnosed by DSM-
IV in various studies.
48 The CES-D scale was found to
be satisfactory in a semi-clinical sample of the elderly
and in general population (sensitivity=0.9 and
specificity=0.6) for life-time MDD and also per-
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Figure 3 Predicting height (a) and IOP (b) in ERF study. Linear regression analysis of height and intraocular pressure.
Percentage of variance represented as difference in R
2 after adjusting for age sex and family relations.
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Molecular Psychiatryformed excellent for 1 month of prevalence of MDD as
diagnosed by DSM-IV (sensitivity=1.0 and specifi-
city=0.9) among elderly Dutch.
49–51 Considering the
HADS-A subscale, the sensitivity and specificity for
DSM-IV generalized anxiety disorder was reported to
be 0.9 and 0.8, respectively.
52 In addition, the
discovery set in this study included lifetime MDD
cases, whereas the Rotterdam study recorded depres-
sive disorders during a 9-year follow-up rather than
lifetime MDD. Similarly, CES-D and HADS measure
depressive and anxious symptoms in the last week.
This means that subjects in the control groups in the
target samples may be non-current but life-time MDD
or anxiety cases. To summarize, although the mea-
surements of anxiety and depression used in the three
study samples are definitely related to each other, the
fact that they are not entirely similar implies some
heterogeneity, biasing the results toward the null
hypothesis.
Another point involves the difference in gender
ratios between discovery and target samples. In the
discovery sample, the cases and controls were care-
fully matched on age and sex. Meta-analysis of twin
studies suggests that genetic factors that influence
depression are mostly shared between men and
women.
1,53,54 Sex was also used as a covariate when
predicting depression or anxiety in the target
samples. Thus, it seems unlikely that the gender ratio
may have a major effect in the replication of the
findings.
There was also heterogeneity in education level as a
measure of socioeconomical status. In spite of these
differences, we still found a significant effect of the
genetic risk score suggesting that the effects of the risk
scores are actually even stronger. In both the Interna-
tional Schizophrenia Consortium study and the
current studies, the low variance explained compared
with the heritability of the disorders will also reflect
that the analyses did not include the X chromosome,
that gene–gene or gene–environment interactions are
not considered and that the current generation of
genotyping platforms do not fully tag genomic
variance.
55
This study is the second study showing direct
evidence for a polygenic component influencing the
susceptibility for a psychiatric disorder as well as
overlap in genetic risk factors with another psychia-
tric condition. In addition, this study suggests that the
genetic factors influencing anxiety and depression
hardly change with age. The results imply that causal
SNPs or the SNPs in LD with such variants do exist,
but have lower effect sizes than the first generation of
GWA studies on psychiatric disorders was powered to
detect. This provides optimism that variants asso-
ciated at genome-wide levels of significance will be
detectable as sample sizes increase in the next
generation of GWA studies and their meta/mega-
analyses. Moreover, it confirms that genome-wide
profiling is a useful approach to analyze the genetic
architecture of disorders, that is, similarities and
differences in genetic factors influencing several
disorders or influencing the same disorder across
the lifespan.
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